FDC Limited (BOM:531599)
361.85
-6.50 (-1.76%)
At close: Mar 6, 2026
FDC Limited Revenue
FDC Limited had revenue of 4.65B INR in the quarter ending December 31, 2025, with 0.13% growth. This brings the company's revenue in the last twelve months to 20.78B, down -0.01% year-over-year. In the fiscal year ending March 31, 2025, FDC Limited had annual revenue of 21.08B with 8.50% growth.
Revenue (ttm)
20.78B
Revenue Growth
-0.01%
P/S Ratio
2.92
Revenue / Employee
3.03M
Employees
6,857
Market Cap
60.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 21.08B | 1.65B | 8.50% |
| Mar 31, 2024 | 19.43B | 1.59B | 8.92% |
| Mar 31, 2023 | 17.84B | 2.56B | 16.74% |
| Mar 31, 2022 | 15.28B | 1.95B | 14.61% |
| Mar 31, 2021 | 13.33B | -109.88M | -0.82% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Procter & Gamble Health | 13.49B |
| Sanofi India | 19.33B |
| Viyash Scientific | 18.17B |
| CORONA Remedies | 13.44B |
| Gufic Biosciences | 8.97B |
| Rubicon Research | 15.98B |
| Caplin Point Laboratories | 20.92B |
| Jubilant Pharmova | 79.18B |
FDC Limited News
- 5 months ago - FDC receives ANDA approval from U.S. FDA for Pilocarpine Hydrochloride Ophthalmic Solution USP - Business Upturn
- 10 months ago - FDC shares drop over 3% as Q4 EBITDA falls 4.2% YoY to Rs 54 crore, net profit down 16.4% YoY - Business Upturn
- 1 year ago - FDC receives US FDA approval for Cefixime 400 mg tablets - Business Upturn
- 1 year ago - FDC shares surge 11%, leading gains in BSE Healthcare index - Business Upturn